Revelation Biosciences (REVB) Registration filing summary

Company overview and business model

• Clinical-stage life science company focused on rebalancing inflammation using proprietary Gemini formulation targeting acute kidney injury, chronic kidney disease, post-surgical infection, and post-burn infection.

• Pipeline includes GEM-AKI, GEM-CKD, GEM-PSI, and GEM-PBI, all based on Gemini, a synthetic TLR4 agonist designed to modulate immune response.

• Incorporated in Delaware in 2019, headquartered in San Diego, CA, with a management team experienced in drug development and commercialization.

Financial performance and metrics

• As of March 31, 2025: $3.7M in cash and cash equivalents, $2.9M in stockholders' equity, and an accumulated deficit of $42.6M.

• Net loss of $15.0M for 2024 and $2.1M for Q1 2025; recurring losses and negative cash flows expected to continue.

• No revenue generated to date; operations funded primarily through equity and warrant issuances raising $56.8M since inception.

Use of proceeds and capital allocation

• Estimated net proceeds of $8.96M (assuming full exercise of Class H-3 Warrants) at an assumed offering price of $3.05 per share.

• Proceeds intended for completion of ongoing Phase 1b clinical study, manufacturing clinical drug supply, additional preclinical work, further product development, and general corporate purposes.

• Funds expected to support operations through at least June 2026, but not sufficient to fund candidates through regulatory approval.